Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AAV- CNGA3

Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx UK II

Phase 1/2 Most advanced trial (none active)
MGTX Developer
1 Registered trials

What is AAV- CNGA3?

AAV-CNGA3 is an adeno-associated virus vector gene therapy that delivers the CNGA3 gene, intended to address defects in that gene. It is being studied in achromatopsia, an inherited color vision disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Ophthalmology
Developer
MeiraGTx UK II Ltd (MGTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
UF5FV8MLZ2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03758404 Phase 1/2 Achromatopsia Completed MGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Achromatopsia

More from MeiraGTx UK II

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MGTX page.

Follow MGTX, the company behind AAV- CNGA3

See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.